Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Spero Therapeutics, Inc. - Common Stock (NQ:SPRO)

0.7730 +0.0720 (+10.27%)
Streaming Delayed Price Updated: 11:07 AM EDT, Apr 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Spero Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers 
Via Benzinga
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Spero Therapeutics, Inc. (SPRO)
From Glancy Prongay & Murray LLP
Via Business Wire
NASDAQ:SPRO Investor Notice: Lawsuit Alleges Misleading Statements by Spero Therapeutics, Inc.
San Diego, CA -- (SBWIRE) -- 06/09/2022 -- An investor, who purchased shares of Spero Therapeutics, Inc. (NASDAQ:SPRO), filed a lawsuit in the over alleged Securities Laws violations by Spero... 
Via SBWire
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Spero Therapeutics, Inc. (SPRO)
From Law Offices of Howard G. Smith
Via Business Wire
Where Spero Therapeutics Stands With Analysts
Within the last quarter, Spero Therapeutics (NASDAQ:SPRO) has observed the following analyst ratings: 
Via Benzinga
Earnings Scheduled For May 16, 2022
Companies Reporting Before The Bell • AcelRx Pharmaceuticals (NASDAQ:ACRX) is estimated to report quarterly loss at $0.06 per share on revenue of $550.00 thousand. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers 
Via Benzinga
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Spero Therapeutics, Inc. (SPRO) Investors
From Glancy Prongay & Murray LLP
Via Business Wire
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Spero Therapeutics, Inc. (SPRO) Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
Stocks That Hit 52-Week Lows On Monday
Monday's session saw 84 companies set new 52-week lows. 
Via Benzinga
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Spero Therapeutics, Inc. (SPRO) Investors
From Law Offices of Howard G. Smith
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Spero Therapeutics, Inc. (SPRO) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
Bronstein, Gewirtz & Grossman, LLC Notifies Spero Therapeutics, Inc. (SPRO) Shareholders of Class Action and Encourages Investors to Contact the Firm
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Spero Therapeutics, Inc. (SPRO) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Spero Therapeutics, Inc. (SPRO) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
Stocks That Hit 52-Week Lows On Thursday
During the Thursday's session, 100 stocks hit new 52-week lows. 
Via Benzinga
SPERO ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Spero Therapeutics, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 73 stocks hit new 52-week lows. 
Via Benzinga
Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Spero Therapeutics, Inc. (SPRO)
From Robbins LLP
Via Business Wire
Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates
May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. New molecular entity approvals, an indicator of innovation in drug research, totaled three during the month,... 
Via Benzinga
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Spero Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Spero Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
EQUITY ALERT: Rosen Law Firm Encourages Spero Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – SPRO
From Rosen Law Firm
Via Business Wire
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 94 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
On Monday, 149 companies reached new 52-week lows. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 20, 2022
Upgrades 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning, investor! It's time for another busy day of trading as we dive into the biggest pre-market stock movers for Tuesday! 
Via InvestorPlace
Recap: Spero Therapeutics Q1 Earnings
Spero Therapeutics (NASDAQ:SPRO) reported its Q1 earnings results on Monday, May 16, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More
Biopharma stocks remained largely unchanged in the week ending May 13, with the defensive nature of the sector coming to its aid. Stocks reacted to the broader market move and earnings news from... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2022
Upgrades 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.